Health
ZetrOZ Systems to Demonstrate Injury-Healing sam 2.0 and sam x1 Units at the Professional Football Athletic Trainer’s Society Membership Presentation March 21
TRUMBULL, Conn., March 21, 2023 (Newswire.com) - As proud 2023-2024 platinum sponsors of the Professional Football Athletic Trainer's Society (PFATS), ZetrOZ Systems will demonstrate its sam® 2.0 and sam® x1 units at an honor reception on Tuesday, March 21, at Wild Horse Pass in Phoenix.Â
ZetrOZ Systems will present clinical data and scientific studies from the past year on the efficacy of sustained acoustic medicine and its injury-healing potential at the PFATS Honors Reception to be held on March 21 from 6-9 p.m. in the Akimel Ballroom of the Sheraton Grand.Â
Dr. George Lewis, founder and CEO of ZetrOZ Systems, will be a guest speaker for the Membership Presentation the following morning, 9:50-10:10 a.m.Â
PFATS provides the highest quality of healthcare to the National Football League and works closely with the NFL Physician Society, National Football League (NFL), and the National Athletic Trainers Association (NATA). It elevates athletic training through research and education to its diverse, 158-plus members across the country, with many of them holding advanced degrees, specialty certifications, and being Certified Athletic Trainers (ATC).
"We're proud to contribute our breakthrough sam® product innovation to PFATS's arsenal of athlete care," Dr. Lewis said. "ZetrOZ Systems works with athletes on all NFL teams — to that end, we're launching a new player performance program that's built around healing daily micro-trauma as an injury prevention measure."
Some of the most common injuries ZetrOZ members face include high-ankle sprains, hamstring tears, and contusions. While, traditionally, athletes have had to navigate injuries and pain management with medication or even surgery, sustained acoustic medicine has been clinically proven by over 40 studies as a non-invasive alternative.Â
The sam® 2.0 and sam® X1 wearable ultrasound devices are the only FDA-cleared units of their kind and can be used daily at home for injury healing, joint pain, and more. By increasing oxygen flow, the removal of cellular waste, and stimulating regeneration, sam® devices boost the body's natural healing propensities, speeding up the recovery process and getting athletes back in action as quickly as possible. With research funded and backed by the National Institutes of Health, National Science Foundation, Department of Defense, NASA, and more, ZetrOZ Systems has risen as an industry leader in soft tissue healing.
To learn more about ZetrOz Systems, visit zetroz.com.
About ZetrOZ Systems
ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of +46 patents and is the exclusive manufacturer and developer of the sam® product line, which is designed for the treatment of acute and chronic musculoskeletal conditions.
Contact Information:Maria Penaloza
[email protected]
Original Source: ZetrOZ Systems to Demonstrate Injury-Healing sam 2.0 and sam x1 Units at the Professional Football Athletic Trainer's Society Membership Presentation March 21
Senzo and Abingdon Health Enter Into Strategic Partnership
PHILADELPHIA, March 20, 2023 (Newswire.com) - Senzo Health Limited (London, UK) ("Senzo") and Abingdon Health PLC (York, UK) ("Abingdon Health") are pleased to announce the signing of a strategic partnership agreement.
Under the terms of the partnership, Abingdon Health will support Senzo by providing contract development and manufacturing ("CDMO") services to Senzo and its partners to enable them to develop and manufacture new rapid tests utilizing Senzo's cutting-edge ALF platform.
Senzo is a leading innovator in the rapid diagnostics testing market, with its revolutionary lateral flow technology delivering the same accuracy as laboratory-based PCR with results available within 10 minutes, at a fraction of the cost. Senzo Health's technology is initially being applied to the development of a Covid-19 antigen assay, a broader respiratory panel, and other infectious disease tests. However, there is a wide range of applications across clinical, animal health, food, plant pathogen and environmental testing that would benefit from the strengths of Senzo's platform technology. This strategic partnership will allow Senzo's partners to accelerate product development through access to Abingdon Health's CDMO services.
Abingdon Health is a leading lateral flow CDMO offering its services to an international customer base across a range of industry sectors. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing, from "idea to commercial success". All projects are managed through Abingdon Health's quality management system, and its services include feasibility, optimization, technical transfer, manufacturing, regulatory and commercial support. Its UK-based automated manufacturing operations are capable of producing tens of millions of lateral flow tests per annum.
Jeremy Stackawitz, CEO of Senzo Health, commented, "This new partnership, with such an established, innovative, and trusted group as Abingdon, is a terrific opportunity for Senzo as we seek to expand the tests being developed and brought to market on our game-changing ALF platform. Collaborating with Abingdon creates a valuable synergy for customers looking to bring innovative, high-performance lateral flow products to market, and we're extremely eager to get to work on the first assays."
Chris Yates, CEO of Abingdon Health, commented, "We are really excited to be working with Senzo and supporting them in leveraging their cutting-edge lateral flow platform technology across multiple applications. We believe this strategic partnership agreement provides Senzo Health and its customers with access to Abingdon's best-in-class CDMO service to enable accelerated product development and time to market."
About Senzo:
Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded to utilize novel technologies, with a focus on enhanced sensitivity, to create mobile, point-of-care and self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products and systems which bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms. With insights generated at the point of care, patients can make better decisions faster, and healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives. www.senzo.com
About Abingdon Health:
Abingdon Health is a leading lateral flow contract development and manufacturing organization ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing, from "idea to commercial success." www.abingdonhealth.com
Alex Mohacs
Sales & Marketing
[email protected]
Original Source: Senzo and Abingdon Health Enter Into Strategic Partnership
